1629654-95-0 - Names and Identifiers
1629654-95-0 - Physico-chemical Properties
Molecular Formula | C89H126N24O18S
|
Molar Mass | 1852.17 |
Density | 1.42±0.1 g/cm3(Predicted) |
pKa | 13.14±0.70(Predicted) |
Storage Condition | -20℃ |
In vitro study | PD-1/PD-L1 Inhibitor 3 was able to inhibit the interaction of PD-L1 with PD-1 and its interaction with cd80. PD-1/PD-L1 Inhibitor 3 has high binding capacity to PD-L1d and can promote enhanced T cell functional activity. |
1629654-95-0 - Introduction
PD-1/PD-L1-IN 3 is a macrocyclic peptide, which is an effective selective PD-1/PD-L1 and CD80/PD-L1 interaction inhibitor, extracted from the patented WO2014151634A1 compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50 being 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for research on various diseases, including cancer and infectious diseases.
Last Update:2022-10-16 17:41:58
1629654-95-0 - Introduction
PD-1/PD-L1 inhibitor 3 is a drug that is used in the treatment of cancer. It acts on the body's immune system, by inhibiting the interaction between PD-1 (programmed death -1) and PD-L1 (programmed death ligand -1), thereby enhancing the body's immune cell's ability to attack tumor cells.
This drug is usually prepared by biopharmaceutical technology, and the specific preparation method involves genetic engineering and cell culture technology. In general, people will extract specific genes from human immune cells, and then introduce them into cell lines for expression and preparation. This method enables mass production of PD-1/PD-L1 inhibitor 3.
Regarding safety information, some side effects may occur with PD-1/PD-L1 inhibitor 3. Common side effects include fatigue, nausea, vomiting, rash, and immune-related inflammatory reactions. Serious side effects may include immune toxicity, such as immune thyroiditis, pneumonia, pancreatitis, etc. Therefore, when using the drug, it is necessary to closely monitor the immune system function of the patient and take timely measures.
It should be noted that PD-1/PD-L1 inhibitor 3 is still in the research and clinical trial stage, and the specific use method and dosage should be determined by the doctor according to the specific situation of the patient. Before use, you should consult a doctor to understand its scope of application, efficacy and safety information to avoid unnecessary risks.
Last Update:2024-04-09 21:54:55